Poseida Therapeutics Stock Today
| PSTX Stock | USD 9.33 0.05 0.53% |
Performance10 of 100
| Odds Of DistressLess than 23
|
Poseida Therapeutics is trading at 9.33 as of the 28th of November 2024; that is 0.53 percent decrease since the beginning of the trading day. The stock's open price was 9.38. Poseida Therapeutics has about a 23 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat ok performance during the last 90 days. Equity ratings for Poseida Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of July 2020 | Category Healthcare | Classification Health Care |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company was incorporated in 2014 and is headquartered in San Diego, California. Poseida Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 97.47 M outstanding shares of which 4.61 M shares are at this time shorted by private and institutional investors with about 8.3 trading days to cover. More on Poseida Therapeutics
Moving against Poseida Stock
Poseida Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Kristin Yarema | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPoseida Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Poseida Therapeutics' financial leverage. It provides some insight into what part of Poseida Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Poseida Therapeutics (PSTX) is traded on NASDAQ Exchange in USA. It is located in 9390 Towne Centre Drive, San Diego, CA, United States, 92121 and employs 350 people. Poseida Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 909.36 M. Poseida Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 97.47 M outstanding shares of which 4.61 M shares are at this time shorted by private and institutional investors with about 8.3 trading days to cover.
Poseida Therapeutics currently holds about 142.56 M in cash with (92.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66.
Check Poseida Therapeutics Probability Of Bankruptcy
Ownership AllocationPoseida Therapeutics owns a total of 97.47 Million outstanding shares. Over half of Poseida Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Poseida Ownership Details
Poseida Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 811.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 726.6 K | |
| Millennium Management Llc | 2024-06-30 | 643 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 567.1 K | |
| Northern Trust Corp | 2024-09-30 | 565.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 563.1 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 501.9 K | |
| Nuveen Asset Management, Llc | 2024-06-30 | 402.9 K | |
| Wellington Management Company Llp | 2024-06-30 | 387.3 K | |
| Fmr Inc | 2024-09-30 | 14.6 M | |
| Pentwater Capital Management Lp | 2024-09-30 | 6 M |
Poseida Therapeutics Historical Income Statement
Poseida Stock Against Markets
Poseida Therapeutics Corporate Management
| Loren Wagner | Senior Operations | Profile | |
| Sarah Thailing | Senior IR | Profile | |
| JD Esq | Chief Counsel | Profile | |
| Johanna CPA | Chief Officer | Profile | |
| Kristin Martin | Chief Officer | Profile | |
| Alexander Chapman | Senior Communications | Profile | |
| Karen MBA | Senior Development | Profile |
Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.